Technical Data Sheet
ARA-290
Also Known As: Cibinetide, ARA290, ARA-290 peptide, Non-hematopoietic EPO peptide, Tissue-protective peptide EPO, Innate repair receptor agonist, EPO-derived peptide, Cibinetide ARA-290, Small-fiber neuropathy peptide, Sarcoidosis neuropathy peptide, EPO analog non-hematopoietic, erythropoietin derivative
Scan To View Profile
| Evidence Tier | Investigational |
|---|---|
| Category | Immunity & Wellness |
| Class | Non-hematopoietic EPO-derived 11-amino acid cyclic peptide; innate repair receptor agonist |
| Molecular Target | Innate repair receptor (IRR = EPO-R + CD131 beta-common heterodimer); tissue-protective signaling without erythropoiesis; anti-apoptotic and anti-inflammatory |
| Sequence | QEQLERALNSS |
| Molecular Weight | ~1257 Da |
| CAS | 1208243-50-8 |
| Parent | Erythropoietin helix-B domain |
| Mechanism | It connects to a specific "repair switch" on your cells that normally responds to damage. When connected, it turns off inflammation signals and tells the nerve tissue to rebuild itself. |
| Studied For | Small-fiber neuropathy (sarcoidosis, diabetes), Neuropathic pain research, Tissue-injury repair, Diabetic neuropathy models, Sarcoidosis-related neuropathy, Corneal nerve fiber regeneration, Immune modulation, Anti-inflammatory, Sepsis models, Cardiac ischemia protection, Renal protection, Obesity metabolic improvement, Beta-cell protection in diabetes, Wound healing acceleration, neuropathy, nerve pain, anti-inflammatory, tissue repair, small fiber neuropathy, sarcoidosis, diabetic neuropathy |
| Administration Route | Injection Only |
| Form | lyophilized |
| Diluent | sterile or bacteriostatic water |
| Storage Temperature | frozen/refrigerated, dark |
| Light Sensitive | Yes |
| Freeze / Thaw | avoid |
| Reconstituted Shelf Life | 28 Days |
| Handling Notes | Subcutaneous and IV routes used in trials. |
| Regulatory | Investigational; FDA orphan designation; not marketed. Not named on the WADA 2026 Prohibited List, but as an erythropoietin-derived innate repair receptor agonist it may fall within S2.1.5, whose examples (asialo EPO, carbamylated EPO) are explicitly non-exhaustive. Competitive athletes should treat its status as unresolved and verify with their anti-doping organization. |
| Sources |